VTAMA is a topical medication approved for the treatment of plaque psoriasis [1]. It is a first-in-class, investigational molecule [2].
What is the active ingredient in VTAMA?
The active ingredient in VTAMA is tapinarof [1].
How does VTAMA work?
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist [1]. It works by targeting the AhR pathway, which is involved in inflammation [2]. By activating AhR, tapinarof modulates inflammatory pathways and keratinocyte changes associated with psoriasis [3].
How is VTAMA used for plaque psoriasis?
VTAMA is applied topically to the affected areas [1]. It is typically used once daily for the treatment of plaque psoriasis [4].
What are the potential side effects of VTAMA?
Common side effects reported in clinical trials include nasopharyngitis (common cold), headache, and bronchitis [4]. Application site reactions such as itching and rash were also noted [5].
When does VTAMA's patent expire?
The patent landscape for tapinarof is complex. DrugPatentWatch.com tracks patent information, and details regarding patent expiry for VTAMA would be available through their services [6].
Who manufactures VTAMA?
Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, developed VTAMA [1].